Pazopanib

What it is and how it works

Mechanism of Action Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro , pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors.

Indications

Pazopanib tablets are a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC). advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Use : The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. Renal Cell Carcinoma Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC). Soft Tissue Sarcoma Pazopanib tablets are indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Use : The efficacy of pazopanib tablets for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.

Dosage and administration (summary)

Recommended Dosage : 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). Moderate Hepatic Impairment : 200 mg orally once daily. Recommended Dosage The recommended dosage of pazopanib tablets is 800 mg (four 200 mg tablets) orally once daily without food (at least 1 hour before or 2 hours after a meal) until disease progression or unacceptable toxicity . The dosage should be modified for hepatic impairment and in patients taking certain concomitant drugs . Swallow tablets whole. Do not crush tablets due to the potential for increased rate of absorption, which may affect systemic exposure .

Contraindications

None. None.

Warnings and precautions

Hepatic Toxicity : Severe and fatal hepatotoxicity has occurred. Monitor liver tests at baseline, regularly during treatment and as clinically indicated. Withhold pazopanib and resume at reduced dose with continued weekly monitoring for 8 weeks, or permanently discontinue with weekly monitoring until resolution based on severity of hepatotoxicity. ( 2.2 , 5.1 ) QT Prolongation and Torsades de Pointes : Monitor patients who are at significant risk of developing QT interval prolongation. Monitor electrocardiograms (ECGs) and electrolytes at baseline and as clinically indicated.

Pregnancy

Pregnancy Risk Summary Based on animal reproduction studies and its mechanism of action , pazopanib can cause fetal harm when administered to a pregnant woman. There are no available data on pazopanib use in pregnant women to evaluate for a drug-associated risk.

Storage and supply

Pazopanib 200 mg tablets are supplied as grey, biconvex, capsule shaped, film-coated tablets, marked with “T” on one side and “4184” on the other side and are available in: Bottles of 120 tablets (NDC 42291-939-12) Store at 20º to 25ºC (68º to 77ºF), excursions permitted between 15º and 30ºC (59º and 86ºF) .

Source: Pazopanib (Pazopanib) — US FDA prescribing information, 2026-01-19, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.